Meyeon Park

MD MAS

Director, Polycystic Kidney Disease Center of Excellence
Nephrologist

Dr. Meyeon Park is a nephrologist who cares for patients affected in various ways by high blood pressure and kidney disease. She has a special focus on polycystic kidney disease (PKD) and directs UCSF's PKD center of excellence.

Park's research explores how heart disease and kidney disease influence each other. She is particularly interested in learning how lifestyle changes can help individuals with PKD.

Park earned her medical degree from the Perelman School of Medicine at the University of Pennsylvania. She then completed a residency in internal medicine at the Yale School of Medicine, followed by a fellowship in nephrology at UCSF. She also has a master of advanced study degree in clinical research from UCSF.

Park is a member of the American Society of Nephrology.

  • Education

    UCSF, M.A.S., Clinical Research, 2012

    Perelman School of Medicine, 2006

  • Residencies

    Yale University School of Medicine, Internal Medicine, 2009

  • Fellowships

    UCSF, Nephrology, 2011

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Nephrology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

  • Languages

    French

    Spanish

Where I see patients (2)

    My reviews

    5.0

    Overall Experience
    76 Ratings
    Explained things in a way that was easy to understand
    75 Ratings
    Did the doctor pay attention to your concerns
    75 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    75 Ratings
    Knew the important information about your medical history
    76 Ratings
    The provider showed respect for what you had to say
    76 Ratings
    The provider spent enough time with me
    76 Ratings
    Read all reviews About our process

    Selected research

    Decorative Caduceus

    A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

    To assess the off-treatment change from baseline in estimated glomerular filtration rate (eGFR) at Week 52 or following a 4-week drug treatment withdrawal period in the first year of treatment, for patients receiving active drug, ...

    Recruiting

    Decorative Caduceus

    APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

    Time from receipt of kidney transplant to death-censored renal allograft failure. Measured in days.

    Recruiting

    Contact me

    Providers on my team

    Share